Federico Mensa
BioNTech (Germany)(DE)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Liver Disease Diagnosis and Treatment, Systemic Lupus Erythematosus Research, Hepatitis B Virus Studies
Most-Cited Works
- → Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection(2018)430 cited
- → Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment(2017)395 cited
- → Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial(2017)339 cited
- → Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis(2017)296 cited
- → Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis(2017)227 cited
- → Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment(2017)201 cited
- → High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis(2018)158 cited
- → Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial(2019)151 cited
- → Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial(2017)145 cited
- → A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease(2024)142 cited